trial

Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism

NCTId NCT02675530
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 33 (actual)
Sponsored by Yale University
Primary completion 2011-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
33 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2007-12
Primary completion
2011-12
Eligibility
ALL · 21 Years · 45 Years

Interventions & indications

Drugs
Ketamine

Sponsors

Yale UniversityLead Sponsor
AstraZenecaCollaborator

Investigators

1
Handan Gunduz-Bruce, M.D.Principal Investigator

Sites

1 total
West Haven, United States

Facts & assertions

4 sourced
Enrollment
33
Phase
PHASE1
Primary Completion Date
2011-12
Status
COMPLETED
relationships
The graph out of here
drug
Ketamine
drug
lead_sponsor
Yale University
company
collaborator
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Handan Gunduz-Bruce, M.D.
person